InsiderPulse| Date | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-01 | Sandler Laura Lee | Chief Operating Officer | Sale | 5,000 | $63.88 | $319K | 237.0K | View ↗ | |
| 2026-03-16 | Sandler Laura Lee | Chief Operating Officer | Sale | 600 | $41.30 | $25K | 237.0K | View ↗ | |
| 2026-03-02 | Sandler Laura Lee | Chief Operating Officer | Sale | 5,000 | $33.56 | $168K | 237.6K | View ↗ | |
| 2026-01-02 | Sandler Laura Lee | Chief Operating Officer | Sale | 13.0K | $28.52 | $371K | 205.1K | View ↗ |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Research and development | $100.6M+34.1% | $75.1M | — | — |
| General and administrative | $21.4M+63.9% | $13.1M+107.9% | $6.3M+7.5% | $5.8M |
| Total operating expenses | $122.1M+38.5% | $88.1M | — | — |
| Loss from operations | -$122.1M-38.5% | -$88.1M-1107.8% | -$7.3M+31.1% | -$10.6M |
| Interest income | $16.6M+183.6% | $5.9M | — | — |
| Interest expense | — | -$1.5M | — | — |
| Other income (expense), net | -$12K-400.0% | $4K | — | — |
| Total other income, net | $16.6M+277.8% | $4.4M | — | — |
| Net loss | -$84.3M-29.6% | -$65.0M-1118.1% | -$5.3M+46.2% | -$9.9M |
| Common Stockholders | ||||
| Net loss | -$84.3M-29.6% | -$65.0M-1118.1% | -$5.3M+46.2% | -$9.9M |
| Net loss per share attributable to stockholders, basic (in Dollars per share) | -$154K+52.3% | -$323K | — | — |
| Net loss per share attributable to stockholders, Diluted (in Dollars per share) | -$154K+52.3% | -$323K | — | — |
| Weighted-average shares used in computing net loss per share attributable to stockholders, basic (in Shares) | $137.1M+164.0% | $51.9M | — | — |
| Weighted-average shares used in computing Net loss per share attributable to stockholders, diluted (in Shares) | $137.1M+164.0% | $51.9M | — | — |
| Series A Non-Voting Convertible Preferred Stockholders | ||||
| Net loss per share attributable to stockholders, basic (in Dollars per share) | -$154K+52.3% | -$323K | — | — |
| Net loss per share attributable to stockholders, Diluted (in Dollars per share) | -$154K+52.3% | -$323K | — | — |
| Weighted-average shares used in computing net loss per share attributable to stockholders, basic (in Shares) | $137.1M+164.0% | $51.9M | — | — |
| Weighted-average shares used in computing Net loss per share attributable to stockholders, diluted (in Shares) | $137.1M+164.0% | $51.9M | — | — |
| Series B Non-Voting Convertible Preferred Stockholders | ||||
| Net loss per share attributable to stockholders, basic (in Dollars per share) | -$154K+52.3% | -$323K | — | — |
| Net loss per share attributable to stockholders, Diluted (in Dollars per share) | -$154K+52.3% | -$323K | — | — |
| Weighted-average shares used in computing net loss per share attributable to stockholders, basic (in Shares) | $137.1M+164.0% | $51.9M | — | — |
| Weighted-average shares used in computing Net loss per share attributable to stockholders, diluted (in Shares) | $137.1M+164.0% | $51.9M | — | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Oruka Therapeutics (ORKA) Reports Positive Phase 2a Results for Psoriasis Treatment ORKA-001
Oruka Therapeutics, Inc. (ORKA) Discusses Interim Results From EVERLAST-A Study of ORKA-001 in Moderate to Severe Plaque Psoriasis - Slideshow
Oruka Therapeutics prices upsized $700M public offering at $72.50 per share
Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering